Deep Intelligence Across Industries

| Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Employees (approx., company boilerplate) | — | 9000 | 9000 | Note: UCB communicates headcount as "approximately 9,000" (2024) and "more than 9,000" (2025). UCB is a Brussels-headquartered, family-anchored global biopharmaceutical company focused exclusively on severe diseases of the immune system and the central nervous system. Over two decades it has transformed from a diversified chemicals-and-pharma conglomerate into a pure-play specialty biopharma, and over the past three years from a CNS/epilepsy-led franchise into an immunology-led growth company. Its flagship, BIMZELX (bimekizumab), the first and only approved dual IL-17A/IL-17F inhibitor, became UCB's largest product in 2025 (€2.23bn net sales) and carries a company peak-sales ambition of at least €7bn, with protection to 2037. Alongside BIMZELX, four further "growth drivers" — FINTEPLA, RYSTIGGO, ZILBRYSQ and EVENITY — generated more than €3.3bn combined in 2025. With 2025 revenue of €7.74bn (+26%), adjusted EBITDA of €2.64bn and no major loss of exclusivity until 2033, UCB is one of Europe's fastest-growing mid-cap pharmaceutical companies, now layering next-generation modalities (T-cell engagers, cell therapy) through acquisitions. --- ### Company's own description In its FY2025 and HY2026 disclosures, UCB describes itself as a global biopharmaceutical company focused on discovering and developing innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system. The IAR 2025 (Note 1) characterises the group as focused on severe diseases in two main therapeutic areas, neurology and immunology, and confirms that the group operates as a single reportable segment, "Biopharmaceuticals" (IAR 2025, Note 3.5), with the Executive Committee as chief operating decision maker. ### Independent characterisation UCB is a vertically integrated, research-based specialty biopharma that: 1. **Discovers** antibodies and other modalities in-house (with a heritage in antibody engineering from Celltech, acquired 2004) and increasingly in-licenses or acquires novel modalities (bispecific/multispecific T-cell engagers from Antengene and Candid; regenerative neural cell therapy from Neurona). 2. **Develops** through global Phase 1–4 programmes, with a late-stage Phase 3 success rate the company cited at 86% in mid-2025 (UCB IR blog, 31 Jul 2025). 3. **Manufactures** biologics and small molecules in an owned network in Belgium (Braine-l'Alleud bioplant and gene therapy facility), Switzerland and elsewhere, supplemented by U.S. contract manufacturers, with a new U.S. biologics campus under development in Georgia. 4. **Commercialises** directly in ~40 countries, with the United States now its dominant market (63% of 2025 net sales before hedging), and through partners in selected geographies (Amgen/Astellas for EVENITY; Nippon Shinyaku for FINTEPLA in Japan; Biogen co-development for dapirolizumab pegol). ### Business model and revenue model | Revenue stream (FY2025) | € million | % of revenue | Nature | |---|---|---|---| | Net sales (products) | 7388 | 95.4 | Product revenue net of rebates, chargebacks, Medicaid/Medicare deductions | | Royalty income and fees | 88 | 1.1 | Licensing of antibody IP ("Biotechnology IP" €54m) and other royalties (€34m) | | Other revenue | 265 | 3.4 | Contract manufacturing for buyers of divested brands (€184m) plus R&D partner payments and milestones (€81m) | | Total revenue | 7741 | 100.0 | — | UCB's revenue model is overwhelmingly product sales of prescription medicines sold to wholesalers, specialty pharmacies, hospitals and government/payer channels. Supplementary revenue streams are: Source: IAR 2025, sections 1.5–1.6. A distinctive feature is that the EVENITY (romosozumab) collaboration with Amgen is mostly not captured in revenue: UCB books only European net sales (€137m in 2025), while its share of worldwide net earnings outside Europe is booked in "other operating income" (€632m in 2025, €379m in H1 2026). This makes EVENITY a far larger profit contributor than its revenue line suggests. There is no subscription or service revenue of note; digital/patient-support services (e.g., UCBCares) are cost centres supporting product sales. ### Value chain position UCB sits at the originator end of the pharmaceutical value chain: target discovery → molecule engineering → clinical development → regulatory → manufacturing → commercialisation. It is a price-setter for patented specialty products but a price-taker vis-à-vis U.S. pharmacy benefit managers (PBMs), Medicaid and European HTA/reimbursement bodies. Gross-to-net management is a core competency, as illustrated by the H1 2026 favourable gross-to-net accrual adjustment and the H2 2026 net price pressure flagged for BIMZELX after a major PBM moved it to first-line coverage effective 1 June 2026 (HY2026 call, as summarised by GuruFocus). ### Customer types and end-markets | Customer / payer type | Relevance | |---|---| | Specialist physicians (dermatologists, rheumatologists, neurologists, epileptologists, neuromuscular specialists, osteoporosis specialists) | Prescribers for all core products | | U.S. specialty pharmacies, wholesalers, PBMs, commercial insurers | Largest channel; U.S. = €4.61bn net sales in 2025 | | U.S. government programmes (Medicaid, Medicare) | Material — Jefferies (Oct 2025) estimated Medicaid at ~27% of the BIMZELX patient base vs ~10% industry average (third-party estimate) | | European national/regional health systems and hospitals | €1.76bn net sales in 2025 | | Japanese health system (NHI price list) | €315m net sales in 2025 | | International markets (Canada, LatAm, APAC ex-Japan, Turkey, etc.) | €612m net sales in 2025 | | Pharma partners and acquirers of divested brands | Contract manufacturing and royalties | **End-markets served:** immuno-dermatology (psoriasis, hidradenitis suppurativa), rheumatology (psoriatic arthritis, axial spondyloarthritis, rheumatoid arthritis), gastroenterology (Crohn's disease, U.S. only for CIMZIA), epilepsy and rare epileptic syndromes (Dravet, Lennox-Gastaut, CDKL5 deficiency disorder), generalised myasthenia gravis, rare mitochondrial disease (TK2 deficiency), postmenopausal osteoporosis (EVENITY, Europe), Parkinson's disease and restless legs (NEUPRO), and allergy (ZYRTEC/XYZAL, established brands).

Company Headquarters: Dublin, Ireland Founded: 2008 Workforce: ~1,000 Company Working: Horizon Therapeutics PLC (Horizon) was formerly knowns as Horizon Pharma PLC. In May 2019 the company changed its name from Horizon Pharma PLC to Horizon Therapeutics PLC. The company believes that the new name reflects its strategy and obligation towards patient care. It is operational in the US, Europe, and other locations worldwide. It has products catering to a wide range of indications such as rheumatology, inflammation, and others. The company has different molecules in the pipeline, which provides it a potential business growth.

Company Headquarters: Durham, North Carolina, US Founded: 2012 Workforce: 700+ Company Working: Bioventus is a major player in the orthobiologics sector. It offers bone stimulation devices, osteoarthritis joint fluid therapies, allogenic morphogenetic proteins, orthobiologics, bone grafts, and allografts to customers all over the world. It operates in business segments including ultrasound bone healing, joint therapies, and bioventus surgical.

Company Headquarters: Massachusetts, US Founded: 1992 Workforce: ~133 Company Working: Anika Therapeutics is an orthopedic and regenerative medicines company. Its offers products based on hyaluronic acid, biocompatible polymer, and natural chemical. In the US, the company owns 19 patents and internationally 187 patents. In 2018, the company’s top five customers account 86% of the revenue, e.g., Mitek, a part of Johnson & Johnson medical device company and the global leader in orthopedic sports medicine accounted 73% of the company sales revenue. The company primarily depends on a small number of large customers, particularly Mitek, for the majority of its sales revenues. The company markets and distribute its products in the US, Italy, and European countries, among others.

Company Headquarters: Amsterdam, Netherlands Founded: 1998 Workforce: 200+ Company Working: uniQure N.V. is engaged in development, manufacturing, and marketing of gene therapy products in the Europe and Americas. The company offers innovative technology, manufacturing platforms, and finished products for the treatment of rare disorders such as hemophilia B, Huntington’s disease, hemophilia A, Fabry disease, and central nervous system disorders. The company offers preclinical services, provide support to the development of drugs, manufacturing and marketing of gene therapy products related to the liver/metabolic, central nervous system and other chronic disorders.

Company Headquarters: Carros, Southeastern France, France Founded: 1968 Workforce: ~4825 Company Working: Virbac develops, manufactures, and markets a wide range of veterinary pharmaceutical products and has a market experience of more than fifty years and is one of the top 10 players in the global animal health market. It operates through the livestock and aquaculture business segments, and manufactures products including parasiticides, immunology, antibiotics/dermatology, specialties, equine, and specialized pet food. The company has a presence in more than 100 countries and generates more than 60% of its revenue from outside Europe. It has 11 manufacturing units in different countries and five fully equipped R&D facilities for the development of products.

Company Headquarters: Greenfield, Indiana, United States Founded: 1954 Workforce: 5,800+ Company Working: Elanco develops and markets products related to animal health all over the world. The company operates through five segments, namely, beef, dairy, poultry, swine, and dogs. The company has a strong presence in more than 90 countries and offers more than 125 brands to the customers. The company was a part of the Eli Lilly group, but due to the spinoff of animal health division Elanco became a separate entity and filed IPO registration.

Company Headquarters: Kenilworth, New Jersey, US Founded: 1944 Workforce: 69,000+ Company Working: MSD & Co. Inc. also known as Merck KGaA in the US and Canada, manufactures and markets innovative medicines, vaccines, and animal health products. MSD & Co. Inc. offers prescribed pharmaceuticals, antibodies, biologic therapies, and animal healthcare items, and it works with clients in more than 140 nations to provide quality products to improve the standard of living. MSD & Co. Inc. likewise focuses on expanding its product portfolio and geographical boundaries through far-reaching strategies, projects, and partnerships. The company operates in over 140 countries to provide advanced health solutions.

Company Headquarters: Lenexa, Kansas, US Founded: 1988 Workforce: ~5500 Company Working: Ceva is a veterinary pharmaceutical company which is into top 10 veterinary health companies. The company operates through several business segments, including companion animals, cattle, poultry, small ruminants, and swine. The company develops and markets products related to reproduction management, anti-infectives treatment, and vaccines. Ceva has a presence in more than 45 countries and has 12 R&D centers and 25 production sites. The company operates in the Americas, Europe, Africa/Middle East, and Asia.

Company Headquarters: Parsippany, New Jersey, United States Founded: 1952 Workforce: 9200+ Company Working: Zoetis is a global animal health company that manufactures, develops, and commercializes pharmaceutical and biological products for animals. It operates through the anti-infectives, vaccines, parasiticides, medicated feed additives, other pharmaceuticals, and other non-pharmaceuticals business segments. It manufactures products for cattle, swine, poultry, fish, and other livestock and companion animals. Zoetis has a wide range of products which provide effective treatment for the animals, and it operates in all the major markets as well as in the developing countries. The company markets more than 200 approved products worldwide.

Company Headquarters: New York, US Founded: 1806 Workforce: ~35,900 Company Working: Colgate-Palmolive, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, namely, oral, personal and home care and pet nutrition. It offers oral care products, including toothpaste, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals. It markets and sells its oral, personal, and home care products to various retail and wholesale customers and distributors.

Company Headquarters: San Diego, US Founded: 2007 Workforce: 115+ Company Working: Organovo Holdings Inc. is a leading biotechnology company which provides 3D bioprinting functional tissues. The company focuses on manufacturing three-dimensional tissues, and these tissues are used in various research and development activities as well as in implant therapies. Moreover, it depends on collaborations and strategic agreements with biopharmaceutical companies, research institutes, and healthcare providers to expand its business. Organovo Holdings Inc. provides products and services related to therapeutic tissues, high-quality human cells (samsara), and disease modeling platform that supports drug discovery and development.

Company Headquarters: Deerfield, Illinois, US Founded: 1931 Workforce: ~50,000 Company Working: Baxter International Inc. (Baxter) is a Fortune 500 American health care company with headquarters in Deerfield, Illinois, US. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. Baxter is a leading producer of intravenous (IV) fluids and systems. It also manufactures infusion pumps, pre-filled syringes, biological sealants, and inhaled anesthetics, as well as dialyzers and other products for the treatment of end-stage renal disease. Its global footprint and critical nature of products and services play a key role in expanding access to healthcare in emerging and developed countries. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. As of December 31, 2018, Baxter manufactured products in over 20 countries and sold them in over 100 countries.

Company Headquarters: Kyoto, Japan Workforce: ~5,944 Founded: 1889 Company Working: Nintendo Co., Ltd (Nintendo) is a Japanese multinational consumer electronics and video game company and is also one of the world's largest in-home entertainment business. Nintendo Co., Ltd (Nintendo) operates in 25 subsidiaries, which are primarily engaged in the development, manufacture, and sale of entertainment products. The company’s goal is to constantly redefine entertainment by offering unique and innovative products. Nintendo’s major products are categorized into computer-enhanced dedicated video game platforms, playing cards, Karuta, and other products. Its most selling video games include Nintendo Entertainment System, Nintendo 64, Nintendo DSi, Nintendo 3DS, and Wii, among others. Over the years, Nintendo has sold more than 4.5 billion video games and more than 710 million hardware units. It operates globally in the UK, France, Italy, Germany, and Spain, among others.

Company Headquarters: Zhejiang, China Founded: 1989 Workforce: 3400 Company Working: Zhejiang Huahai Pharmaceuticals Co., Ltd, is a large scale pharmaceutical company that integrates formulations of active pharmaceutical ingredients (API) and intermediates for developing both domestic and international markets. The firm has a total asset of 1,900 million yuan, with 11 branches (subsidiaries) in the US, Shanghai, Hangzhou, and Linhai. The company is entitled as the National Key Hi-tech Enterprise, National Pilot Enterprise of Innovation is among China's top 500 private enterprises, and also possesses a "State Certified Enterprise Technology Center." The company's workshops of the formulation are designed in strict compliance with the international cGMP standard.

Company Headquarters: Japan Founded: 1919 Workforce: 46,500 Company Working: Olympus Corporation is a Japanese multinational corporation that specializes in manufacturing and selling optical and reprography products, as well as medical and surgical equipment. The company was founded in 1919 and is headquartered in Tokyo, Japan. Olympus Corporation is organized into four main business segments: Medical, Scientific Solutions, Imaging, and Financial. The Medical segment is the largest and most important business segment of the company, accounting for approximately two-thirds of the company's total revenue. The Medical segment includes endoscopy and surgical products, as well as clinical and research microscopes which includes Biopsy devices. Within the Medical segment, Olympus Corporation offers a range of products for minimally invasive surgical procedures, including endoscopes and endotherapy devices. One of the key products offered by Olympus Corporation is its biopsy device, which is used to collect tissue samples from various parts of the body for diagnostic purposes. Olympus Corporation's biopsy device is designed to be used with endoscopes and comes in a range of sizes and shapes to suit different clinical needs. The company has a global presence with operations in various regions around the world. The company's headquarters is located in Tokyo, Japan, and it has several subsidiaries and offices in different countries.

Zydus Lifesciences is transitioning from a volume generics exporter into a branded, innovation-weighted global life-sciences company. Management states that branded products now exceed 55% of consolidated revenue and that branded sales within the United States have reached 11% (Q1 FY27). The company is the third-largest generic pharmaceutical company in the US by prescription volume, holds a top-tier position in Indian branded formulations with leadership in oncology, and owns India's most commercially credible new-chemical-entity franchise in Lipaglyn (saroglitazar) and Oxemia (desidustat). FY26 revenue of ₹27,148 crore (~US$3.07 billion) was the company's highest ever, with a record 31.2% EBITDA margin. Three inorganic moves in eighteen months — Comfort Click in consumer wellness, Amplitude Surgical in orthopaedic devices, Agenus' California biologics plants and Assertio in US specialty oncology — have simultaneously diversified the earnings base and, for the first time in a decade, levered the balance sheet. The central investment question is whether specialty and biosimilar scale-up outruns Revlimid and Mirabegron erosion. Zydus Lifesciences Limited is the listed flagship of the Ahmedabad-based Zydus Group and India's fifth-to-sixth largest pharmaceutical company by revenue. It is a vertically integrated, increasingly innovation-led life-sciences business spanning branded formulations in India, generics and specialty pharmaceuticals in North America, emerging-market and European formulations, active pharmaceutical ingredients, consumer wellness (through the separately listed subsidiary Zydus Wellness), medical technology, vaccines, biosimilars and — since January 2026 — US-based biologics contract manufacturing. --- **What the company does.** Zydus discovers, develops, manufactures and markets a broad range of healthcare therapies: small-molecule generics, branded prescription formulations, biologics and biosimilars, vaccines, active pharmaceutical ingredients, consumer wellness products, and — most recently — orthopaedic implants and biologics contract manufacturing services. The company's own framing, repeated verbatim in its earnings releases, is that of "an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies," operating under "an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives." **Independent characterisation.** Zydus is best understood as four businesses of very different economic character stapled to a common Indian manufacturing and R&D base: 1. **A US generics volume machine (~40-44% of revenue).** Commodity-priced, high-working-capital, exposed to distributor consolidation and price erosion, but defended by scale — 513 cumulative ANDA filings and 448 approvals as at 30 June 2026 — and by first-to-file/CGT exclusivity opportunism. Earnings here are lumpy and event-driven, dominated in recent years by generic Revlimid (lenalidomide) and generic Myrbetriq (mirabegron), both of which are now rolling off. 2. **An Indian branded prescription franchise (~24-25% of revenue).** Annuity-like, chronic-weighted, priced above generics, with distribution scale and physician relationships as the moat. Chronic and sub-chronic therapies reached 54.2% of the India book by MAT June 2026 (AWACS), up 360 basis points over four years. 3. **A consumer wellness FMCG business (~15-20% of revenue).** Held through the separately listed Zydus Wellness Limited. Brand-driven, seasonal, low regulatory risk, and — since Comfort Click — increasingly a cross-border e-commerce/D2C vitamins business rather than a purely Indian one. 4. **An emergent specialty/innovation portfolio.** Rare disease (Zycubo, Nulibry via Sentynl), 505(b)(2) reformulations (Beizray), biosimilars (Nufymco, Tishtha, Anyra), NCEs (saroglitazar, desidustat, zintrodiazine), MedTech (Amplitude Surgical) and CDMO (Zylidac Bio). This is where management is directing incremental capital, and where none of the assets is yet individually material to consolidated revenue. **Revenue model.** Overwhelmingly product sales rather than services or subscription. Three secondary streams exist: (a) out-licensing income — desidustat was licensed to China Medical System Holdings in 2020 and reached Chinese approval in FY26; (b) alliance/contract income, reported as "Alliances & Others" and now near-immaterial at ₹571 million in FY26 (down 64% year on year); and (c) from FY27, contract development and manufacturing fees through Zylidac Bio LLC, which carries an exclusive manufacturing arrangement with Agenus for botensilimab and balstilimab plus a first right of negotiation on Agenus' future pipeline. **Value chain position.** Unusually integrated for an Indian pharmaceutical company: captive API manufacture (with the pending Sterling Biotech API acquisition intended to deepen this), formulation manufacture across 44 facilities, in-house biologics drug substance and drug product capability, its own US front-end distribution (Zydus Pharmaceuticals USA, Viona, Sentynl, Zydus Therapeutics), and now US-domiciled biologics manufacturing. **Customer types and end-markets.** In India: distributors and stockists selling into ~800,000 retail pharmacies, plus hospitals and institutional/government tenders (notably vaccines). In the US: the three large drug purchasing consortia and wholesalers (whose bargaining power drives the group's 188-day gross current asset cycle), plus specialty pharmacy and buy-and-bill oncology channels for Rolvedon and the biosimilars. In emerging markets and Europe: a mix of own subsidiaries (France, Spain, Brazil, South Africa, Mexico, Philippines, Sri Lanka, Myanmar) and third-party distributors. In consumer wellness: modern trade, general trade, e-commerce and, post-Comfort Click, direct-to-consumer digital channels in the UK, EU and US.

Company Headquarters: New York, US Founded: 2007 Workforce: 7000+ Company Working: Carestream Health is a medical imaging and information technology health company. The company develops diagnostic tools such as digital X-ray machines, mammography equipment, radiography, molecular imaging, and related supplies. It has strong research and development department and holds more than 600 patents in the area of digital imaging, healthcare IT, film, and imaging chemistry. It is present in all the major markets and covers more than 150 countries.

Company Headquarters: New York, US Founded: 1946 Workforce: ~46,000 Company Working: Estée Lauder Inc. offers skincare, makeup, and fragrance products. The company has brands, namely, AERIN, Aramis, Aveda, BECCA, Bobbi Brown, Bumble and bumble, By Kilian, Clinique, Darphin, Donna Karan New York, DKNY, Editions de Parfums Frédéric Malle, Ermenegildo Zegna, Estée Lauder, GLAMGLOW, Jo Malone London, Kiton, La Mer, Lab Series, Le Labo, M•A•C, Michael Kors, Origins, Prescriptives, RODIN olio Lusso, Smashbox, Tom Ford, Tommy Hilfiger, Too Faced and Tory Burch. Its products are sold in more than 135 countries and territories.

Company Headquarters: Linköping, Sweden Founded: 1978 Workforce: 706 Company Working: Sectra AB (Sectra) is a technology company based in Sweden. The company has customers in around 60 countries, out of which it sells its products directly in 19 countries and via partners in remaining countries. Sectra AB operates through four operating segments, namely, imaging IT solutions, secure communications, business innovation, and spectra customer financing. The imaging IT solutions segment manufactures and sells medical IT systems and services, and also offers maintenance in the form of support, business development, system monitoring, system design, and consulting services related to integration and data migration.

Company Headquarters: Hamburg, Germany Founded: 1945 Workforce: 3367 Company Working: Eppendorf AG (Eppendorf) is a leading life science company that is engaged in the development of instruments, consumables, and services for liquid, sample, and cell handling in laboratories all around the globe. It offers a wide range of products that include pipettes and automated pipetting systems, spectrometers, dispensers, centrifuges, mixers, and DNA amplification equipment as well as ultra-low temperature freezers, bioreactors, CO2 incubators, fermenters, shakers, and cell manipulation systems. With these products, it serves various industries such as pharmaceutical, biotechnology, chemical, and food. The company focuses on clinical and environmental analysis laboratories, forensics, and industrial laboratories performing process analysis, production, and quality assurance. Geographically, it operates in more than 25 countries in regions such as Europe, North America, and Asia.

Company Headquarters: Paris, France Founded: 1929 Workforce: ~ 5,400+ Company Working: Ipsen Pharma is a global pharmaceutical company operating in two segments, namely, specialty care and consumer healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rare disease areas. In the neuroscience segment, the company provides products for the treatment of cervical dystonia, adult spasticity, blepharospasm, hemifacial spasm, hyperhidrosis, and pediatric lower limb spasticity. Ipsen Pharma operates as a subsidiary of Mayroy S.A. The company has R&D centers and manufacturing sites located in China, France, Ireland, the UK, and the US. Ipsen Pharma is present in more than 115 countries and has a direct presence through corporates offices in around 35 countries across the globe.

Company Headquarters: Massachusetts, US Founded: 1984 Workforce: 11-50 Employees Company Working: Safety 1st is a subsidiary of Dorel Industries Inc. The company deals in home security products, child safety products and childcare, and convenience and activity products. Safety 1st is known for its famous yellow BABY ON BOARD sign. It supplies a lot of novel and innovative products to parents to help them in keeping their child safe. As the company is privately held, the financial information mentioned is of the parent company, Dorel Industries

Company Headquarters: Georgia, US Founded: 1942 Workforce: 500-1000 Employees Company Working: Graco Children’s Products Inc. is a subsidiary of Newell Brands. It is a recognized leader of manufacturing baby products. The company provides thoughtful, practical, and dependable parenting solutions to families. It manufactures intuitive and user-friendly products. Its product range includes strollers, car seats, high chairs, playards, monitors, swings, soothers, activity center products, travel systems, audio digital/audio analog/prenatal monitors, doorway jumpers, nursery care products, and many more.

Company Headquarters: Chicago, US Founded: 1928 Workforce: 10000+ Employees Company Working: Motorola Home provides numerous products in the global market such as modems and networking, chargers and power banks, cases, music and sound, cordless phones, and baby monitors. The company has a strong brand name and distribution network all over the world.

Company Headquarters: Canada Founded: 1991 Workforce: 200 Employees Company Working: The company is into the development and manufacturing of video security systems. Lorex Technology Inc. provides cloud-based security systems for personal as well as corporate use. The company operates in segments such as security cameras, wireless security cameras, internet protocol cameras (IP cameras), security digital video recorder (DVR), security camera systems, HD security camera system, and lorex security camera accessories Lorex Technology Inc. is a subsidiary of FLIR Systems Inc. Hence, the below financial information provided is of FLIR Systems Inc.

Company Headquarters: Massachusetts, US Founded: 1949 Workforce: 150+ Employees Company Working: The first years Inc. is a global juvenile products brand. The company is a major manufacturer and distributor of baby care products. The company operates in three segments, namely, feeding and soothing, play and discover, and care and safety. The company also offers products such as bathing and grooming products, toys, teethers, bath toys, books, stroller toys, and rattles. The first years Inc is a subsidiary of RC corporation which is under the control of Tomy Company, Ltd. Hence, the below financial information provided is of Tomy Company, Ltd.